Susquehanna International Group, LLP Adagio Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	BUY	N/A	44,800 New	44,800 $148,000
Q4 2022 Feb 14, 2023	SELL	$3.08 - $4.05 $32,032 - $42,120	-10,400 Reduced 48.83%	10,900 $36,000
Q3 2022 Nov 14, 2022	SELL	$2.97 - $4.83 $264,330 - $429,870	-89,000 Reduced 80.69%	21,300 $67,000
Q2 2022 Aug 15, 2022	BUY	$2.54 - $4.52 $212,852 - $378,775	83,800 Added 316.23%	110,300 $362,000
Q1 2022 May 16, 2022	SELL	$3.81 - $10.77 $41,529 - $117,393	-10,900 Reduced 29.14%	26,500 $121,000
Q4 2021 Feb 14, 2022	BUY	$6.35 - $47.04 $237,490 - $1.76 Million	37,400 New	37,400 $272,000

67.3M

720K

600

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.